# SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

> **NCT06835179** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 28 (estimated)

## Conditions studied

- Unresectable Metastatic Colorectal Cancer
- Microsatellite Stable (MSS) Colorectal Cancer (CRC)
- RAS-mutant Colorectal Cancer

## Interventions

- **RADIATION:** SBRT
- **DRUG:** PD-1 Inhibitors
- **DRUG:** CapeOX + bevacizumab

## Key facts

- **NCT ID:** NCT06835179
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2027-02
- **Final completion:** 2027-05
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06835179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06835179, "SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06835179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*